# US 2019/0315866 A1 · Antibodies Directed Against ICOS and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315866 A1
- Document ID: US20190315866A1
- Status: Published application
- Kind: A1
- Application number: 16/452,984
- Filed: 2019-06-26
- Published: 2019-10-17
- Earliest claimed: 2011-03-31
- Assignees: Inserm (Institut National De La Sante Et De La Recherche Medicale); Institut Jean Paoli & Irene Calmettes; Universite D'Aix-Marseille; Universite Claude Bernard Lyon 1; Centre Leon Berard
- Applicants: Inserm (Institut National De La Sante Et De La Recherche Medicale); Institut Jean Paoli & Irene Calmettes; Universite D'Aix-Marseille; Universite Claude Bernard - Lyon 1; Centre Leon Berard
- Inventors: Julien Faget; Christophe Caux; Christine Menetrier-Caux; Jacques Nunes; Daniel Olive
- Web page: https://patentgrep.com/patent/US20190315866A1

## CPC

- C07K 16/2818: {against CD28 or CD152}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/04: for throat disorders
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- G01N 33/56972: {White blood cells}
- G01N 33/57515: of the breast
- A61K 2039/505: {comprising antibodies}
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/75: Agonist effect on antigen
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-O and IFNγ production, induce CD4− T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.

## Claims

### Claim 1

A method of treatment of cancer in a patient in need thereof, the method comprising administering to the patient an antibody directed against human Inducible T-cell costimulator (ICOS), wherein said antibody reduces the number and/or activity of regulatory T cells (Treg cells) in a tumor microenvironment.

### Claim 2 (depends on 1)

The method of claim 1, wherein said antibody binds human ICOS with an ED50 of less than about 10 μg/ml, less than about 5 μg/ml, less than about 1 μg/ml, less than about 0.5 μg/ml, or less than about 0.1 μg/ml.

### Claim 3 (depends on 1)

The method of claim 1, wherein said antibody reduces the number of Treg cells in a tumor microenvironment.

### Claim 4 (depends on 1)

The method of claim 1, wherein said antibody reduces the activity of Treg cells in a tumor microenvironment.

### Claim 5 (depends on 1)

The method of claim 1, wherein the cancer is human malignant lymphoma.

### Claim 6 (depends on 1)

The method of claim 1, wherein said cancer is ovarian cancer.

### Claim 7 (depends on 1)

The method of claim 1, wherein said cancer is cervical cancer.

### Claim 8 (depends on 1)

The method of claim 1, wherein said cancer is breast cancer.

### Claim 9 (depends on 1)

The method of claim 1, wherein said cancer is colon cancer.

### Claim 10 (depends on 1)

The method of claim 1, wherein said cancer is lung cancer.

### Claim 11 (depends on 1)

The method of claim 1, wherein said cancer is prostate cancer.

### Claim 12 (depends on 1)

The method of claim 1, wherein said cancer is head and neck cancer.

### Claim 13 (depends on 1)

The method of claim 1, wherein said cancer is pancreatic cancer.

### Claim 14 (depends on 1)

The method of claim 1, wherein said cancer is bladder cancer.

### Claim 15 (depends on 1)

The method of claim 1, wherein said cancer is colorectal cancer.

### Claim 16 (depends on 1)

The method of claim 1, wherein said cancer is kidney cancer.

### Claim 17 (depends on 1)

The method of claim 1, wherein said cancer is stomach cancer.

### Claim 18 (depends on 1)

The method of claim 1, wherein said cancer is skin cancer.

### Claim 19 (depends on 1)

The method of claim 1, wherein said cancer is esophageal cancer.
